Luana dos Santos Ribeiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luana dos Santos Ribeiro has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Braga
Department of Gynecology and Obstetrics, School of Medicine, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 22240-003, RJ, Brazil
2 shared publications - Edward Araujo Júnior
Department of Obstetrics Paulista School of Medicine, Federal University of São Paulo (EPM‐UNIFESP) São Paulo Brazil
2 shared publications - Gloria Calagna
Villa Sofia Cervello Hospital, University of Palermo, 90100 Palermo, Italy
2 shared publications - Gustavo Yano Callado
Albert Einstein Israelite College of Health Sciences (FICSAE), Albert Einstein Israelite Hospital, São Paulo 05652-900, SP, Brazil
2 shared publications - Isadora Rodrigues Almeida
Discipline of Woman Health, Municipal University of São Caetano do Sul (USCS), São Caetano do Sul 09521-160, SP, Brazil
2 shared publications - Manuela Cândido Amaral dos Reis
Discipline of Woman Health, Municipal University of São Caetano do Sul (USCS), São Caetano do Sul 09521-160, SP, Brazil
2 shared publications
Latest Publications
- Open Access
Beyond the Adolescent Window: HPV Vaccination in Adult Women
Human papillomavirus (HPV) vaccination has traditionally targeted girls and adolescents before sexual debut, when its preventive potential is greatest. However, many women reach adulthood unvaccinated or incompletely vaccinated, a gap widened by the COVID-19 pandemic. This narrative review summarizes the current evidence on HPV vaccination in adult women and its implications for gynecological practice. Sexual debut, previous infection, or a positive HPV test does not preclude benefit, because few women have been exposed to all vaccine types; nevertheless, the vaccine is prophylactic and does not treat established infection or lesions. In women aged 27 to 45 years, trials show favorable immunogenicity, efficacy, and safety, and vaccination is recommended through shared clinical decision-making that considers prior exposure and the risk of new exposures. Evidence above 45 years of age remains scarce. After excisional treatment of cervical intraepithelial neoplasia grade 2 or worse, meta-analyses predominantly based on observational studies suggest lower recurrence rates following adjuvant vaccination, although this benefit has not been consistently confirmed by randomized controlled trials. We also discuss additional vaccination with the nonavalent vaccine after bivalent or quadrivalent series, single-dose schedules, people living with HIV, and cervical screening in vaccinated women, in whom HPV-based testing maintains better performance than cytology. Missed opportunities remain common, and the absence of a recommendation from a health care professional is among the main reasons adults remain unvaccinated. Reviewing vaccination history at every gynecological visit, combined with individualized counseling, may help close the gap between vaccinated young cohorts and unvaccinated adult women and support cervical cancer elimination goals.
Open AccessBeyond the Adolescent Window: HPV Vaccination in Adult Women
Human papillomavirus (HPV) vaccination has traditionally targeted girls and adolescents before sexual debut, when its preventive potential is greatest. However, many women reach adulthood unvaccinated or incompletely vaccinated, a gap widened by the COVID-19 pandemic. This narrative review summarizes the current evidence on HPV vaccination in adult women and its implications for gynecological practice. Sexual debut, previous infection, or a positive HPV test does not preclude benefit, because few women have been exposed to all vaccine types; nevertheless, the vaccine is prophylactic and does not treat established infection or lesions. In women aged 27 to 45 years, trials show favorable immunogenicity, efficacy, and safety, and vaccination is recommended through shared clinical decision-making that considers prior exposure and the risk of new exposures. Evidence above 45 years of age remains scarce. After excisional treatment of cervical intraepithelial neoplasia grade 2 or worse, meta-analyses predominantly based on observational studies suggest lower recurrence rates following adjuvant vaccination, although this benefit has not been consistently confirmed by randomized controlled trials. We also discuss additional vaccination with the nonavalent vaccine after bivalent or quadrivalent series, single-dose schedules, people living with HIV, and cervical screening in vaccinated women, in whom HPV-based testing maintains better performance than cytology. Missed opportunities remain common, and the absence of a recommendation from a health care professional is among the main reasons adults remain unvaccinated. Reviewing vaccination history at every gynecological visit, combined with individualized counseling, may help close the gap between vaccinated young cohorts and unvaccinated adult women and support cervical cancer elimination goals.
- Open Access
Maternal Immunization Against Respiratory Syncytial Virus: An Integrative Review of Efficacy, Safety, and Implementation
Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infection in young infants and accounts for substantial morbidity, hospitalization, and mortality worldwide, with the highest burden concentrated in the first months of life, when immunological and anatomical immaturity favors severe disease. Maternal vaccination has emerged as a strategy to bridge this window of vulnerability through the transplacental transfer of neutralizing antibodies. This integrative review synthesizes scientific articles published between 2022 and 2026, including systematic reviews, meta-analyses, narrative reviews, and position statements from national and international scientific societies, addressing the epidemiology, clinical manifestations, diagnosis, mechanism of action, efficacy, safety, and public health impact of maternal RSV immunization. The bivalent prefusion F protein vaccine (RSVpreF; Abrysvo®), administered as a single intramuscular dose between 32 and 36 weeks of gestation, induces maternal IgG that is transferred to the fetus and confers passive protection during the first six months of life. In the phase 3 MATISSE trial, vaccination demonstrated 81.8% efficacy against severe RSV lower respiratory tract infection within 90 days of birth and 69.4% within 180 days, alongside reductions in hospitalization. The safety profile was favorable, with predominantly mild and transient adverse events; a numerical imbalance in preterm birth remains under surveillance and underlies the precautionary gestational window. Maternal vaccination and long-acting monoclonal antibodies (nirsevimab) are best regarded as complementary rather than competing strategies. Current evidence supports maternal immunization as one of the most effective measures to reduce the burden of RSV disease in early infancy.
Open AccessMaternal Immunization Against Respiratory Syncytial Virus: An Integrative Review of Efficacy, Safety, and Implementation
Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infection in young infants and accounts for substantial morbidity, hospitalization, and mortality worldwide, with the highest burden concentrated in the first months of life, when immunological and anatomical immaturity favors severe disease. Maternal vaccination has emerged as a strategy to bridge this window of vulnerability through the transplacental transfer of neutralizing antibodies. This integrative review synthesizes scientific articles published between 2022 and 2026, including systematic reviews, meta-analyses, narrative reviews, and position statements from national and international scientific societies, addressing the epidemiology, clinical manifestations, diagnosis, mechanism of action, efficacy, safety, and public health impact of maternal RSV immunization. The bivalent prefusion F protein vaccine (RSVpreF; Abrysvo®), administered as a single intramuscular dose between 32 and 36 weeks of gestation, induces maternal IgG that is transferred to the fetus and confers passive protection during the first six months of life. In the phase 3 MATISSE trial, vaccination demonstrated 81.8% efficacy against severe RSV lower respiratory tract infection within 90 days of birth and 69.4% within 180 days, alongside reductions in hospitalization. The safety profile was favorable, with predominantly mild and transient adverse events; a numerical imbalance in preterm birth remains under surveillance and underlies the precautionary gestational window. Maternal vaccination and long-acting monoclonal antibodies (nirsevimab) are best regarded as complementary rather than competing strategies. Current evidence supports maternal immunization as one of the most effective measures to reduce the burden of RSV disease in early infancy.